Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Manmeet S AhluwaliaDavid A ReardonAjay P AbadWilliam T CurryEric T WongSheila A FigelLaszlo L MechtlerDavid M PeereboomAlan D HutsonHenry G WithersSong LiuAhmed N BelalJingxin QiuKathleen M MogensenSanam S DharmaAndrew DhawanMeaghan T BirkemeierDanielle M CasucciMichael J CiesielskiRobert A FenstermakerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.
Keyphrases